Glenmark Pharmaceuticals Ltd (GLENMARK) is currently trading at 2,306.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Glenmark Pharmaceuticals Limited is actively involved in the development, manufacture, and marketing of pharmaceutical products, focusing on formulations and active pharmaceutical ingredients. Its core areas include oncology, respiratory, and dermatology, serving major global markets. The company’s Q3 FY26 results emphasize a consolidated revenue surge of 15.1% YoY, underscoring its robust execution across international markets, particularly India, which saw 22.1% growth buoyed by strong performance in dermatology and respiratory therapies. Glenmark’s diverse and innovative pipeline is scaling globally, exemplified by substantial launches such as RYALTRIS and WINLEVI, which are experiencing strong uptake in Europe, the UK, and planned introductions in new markets, projecting future growth. Strategic international partnerships, particularly in North America, boost Glenmark’s market capabilities, as highlighted by their new injectable product launches and ANDA filings, alongside regulatory successes supporting their expansion narratives. Glenmark anticipates continued strength from their current momentum, underscored by regulatory progress in Monroe, North America, and innovative product introductions that drive their transformation into a more innovation-led entity.

Over the past 52 weeks, Glenmark Pharmaceuticals Ltd has traded between a low of ₹1,794.00 and a high of ₹2,471.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Glenmark Pharmaceuticals Ltd has a market capitalization of approximately 65,081.01. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Glenmark Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 36.20 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 65,081.01 Cr, Glenmark Pharmaceuticals Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Glenmark Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Glenmark Pharmaceuticals Ltd is 36.20. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The board approved Glenmark’s unaudited results in a meeting held on July 31, 2026, for the quarter ended June 30, 2026.

Glenmark Pharmaceuticals has declared an interim dividend of ₹2.50 per equity share (face value Re 1) for FY2025-26.

Glenmark 3.0 is the company’s strategy to move up the value chain toward an innovation-led model, while scaling branded products and maintaining a large commercial footprint.

Glenmark, via Glenmark Specialty S.A., signed an exclusive license and collaboration agreement with Hengrui for Trastuzumab Rezetecan, with $18 million upfront and up to $1,093 million in milestones plus royalties.